Scarica l'app Stockscreener
132.07
0.50%
-0.8652
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$132.94
Aprire:
$133.105
Volume 24 ore:
2.16M
Relative Volume:
0.31
Capitalizzazione di mercato:
$229.85B
Reddito:
$42.34B
Utile/perdita netta:
$13.50B
Rapporto P/E:
17.13
EPS:
7.71
Flusso di cassa netto:
$6.66B
1 W Prestazione:
-0.59%
1M Prestazione:
+2.12%
6M Prestazione:
+11.20%
1 anno Prestazione:
+29.74%
Intervallo 1D:
$132.04
$133.60
Intervallo di 1 settimana:
$130.43
$133.84
Portata 52W:
$99.71
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Confronta ABT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
132.11 | 235.23B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.56 | 157.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.75 | 148.87B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
81.32 | 110.72B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.72 | 45.66B | 5.54B | 4.18B | 623.10M | 7.00 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Abbott Laboratories (NYSE:ABT) Gains FDA Nod For Tendyne Mitral Valve System - Yahoo Finance
Abbott (ABT) Gains Marginal Benefit from Boston Scientific's Str - GuruFocus
Abbott Stock Gains Following FDA Approval of the Tendyne System - Yahoo
The Zacks Analyst Blog Highlights Coca-Cola, Abbott Laboratories and AT&T - Yahoo Finance
Cardiac Implants Market Is Booming Worldwide | Abbott - openPR.com
Abbott Gains FDA Approval for Tendyne™, Strengthening Its Minimally Invasive Heart Portfolio - Yahoo Finance
Abbott Stakes Claim in TMVR Market with New FDA Approval - Medical Device and Diagnostic industry
Top Stock Reports for Coca-Cola, Abbott & AT&T - Nasdaq
Abbott Laboratories’ SWOT analysis: diversified portfolio bolsters stock amid challenges - Investing.com
FDA approves self-expanding Tendyne TMVR device from Abbott - Cardiovascular Business
Abbott wins approval for open-heart surgery-free valve replacement - Crain's Chicago Business
Biochips Market Poised Boom | Abbott Laboratories, Agilent Technologies, Inc., PerkinElmer, Inc - openPR.com
Abbott Labs (ABT) Receives FDA Approval for Tendyne Heart Valve System - GuruFocus
FDA approves Abbott mitral valve replacement device that doesn't require open-heart surgery - MassDevice
Abbott gets FDA nod for Tendyne valve for mitral valve disease - Seeking Alpha
Abbott Says Tendyne Transcatheter Mitral Valve Replacement System Receives FDA Approval - marketscreener.com
Abbott’s Tendyne valve gets FDA nod for mitral replacement By Investing.com - Investing.com Canada
Abbott (ABT) Receives FDA Approval for Tendyne Heart Valve System | ABT Stock News - GuruFocus
Abbott’s Tendyne valve gets FDA nod for mitral replacement - Investing.com
Oman Dietary Supplements Market Forecast Report to 2030, with Profiles of Nature's Way, Amway, Pfizer Gulf, Abbott Laboratories, Herbalife Nutrition, Nestle & Oman Pharmaceutical Products - GlobeNewswire
A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Abbott Laboratories: Why Wall Street's Skepticism Misses The Real Story - Seeking Alpha
If You Invested $10K In Abbott Laboratories Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
Abbott Laboratories (ABT) Benefitted From Better Execution - MSN
STHS unveils groundbreaking lab upgrade from Abbott at St. Tammany Parish Hospital - an17.com
Abbott Laboratories (NYSE:ABT) Collaborates On Advanced Diabetes Management With Glucose-Ketone Sensor Integration - simplywall.st
Abbott Laboratories (ABT) was up 16% in Q1 - Insider Monkey
Was Jim Cramer Right About Abbott Laboratories (ABT)? - MSN
2 Dividend Stocks to Buy With $500 and Hold Forever - The Motley Fool
Blood Glucose Monitoring (BGM) Devices Market Report 2025: Hospitals Lead in Blood Glucose Monitoring Device Usage, Home Care Grows Fastest - GlobeNewswire Inc.
From Acquisition to Advantage: Abbott's Growth in Heart Care - Yahoo Finance
Abbott vs. Medtronic: Which Dividend-Paying MedTech Stock is Better? - Yahoo Finance
Researchers question reliability of Abbott’s rapid malaria tests - Science | AAAS
Senseonics Holdings, Inc. Secures $57.5 Million in Public Offering and $20.3 Million from Private Placement with Abbott Laboratories - Nasdaq
Senseonics Secures Massive $77.8M Funding Boost as Abbott Backs Next-Gen Diabetes Monitor Launch - Stock Titan
The Growth Of Medical Devices Needs To Continue In Order To Invest In Abbott (NYSE:ABT) - Seeking Alpha
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Do Abbott Laboratories' (NYSE:ABT) Earnings Warrant Your Attention? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Alcon (ALC) - The Globe and Mail
Solid Results Boosted Abbott Laboratories’ (ABT) Performance in Q1 - Insider Monkey
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views? - Nasdaq
Biotechnology Market Set to Witness Significant Growth by 2025-2032 | Abbott Laboratories, Amgen Inc., - EIN News
United States Generic Drugs Market Forecast and Company Analysis Report 2025-2033 Featuring Teva Pharma, Aurobindo Pharma, Sun Pharma, Abbott Laboratories, Lupin Pharma, Viatris, Sandoz, Dr. Reddy'sResearchAndMarkets.com - FinancialContent
Abbott Laboratories (ABT)’s Libre Linked to Fewer Heart Hospitalizations in Diabetes - MSN
Abbott Reveals Positive Outcome From REFLECT Studies, Stock Climbs - Zacks Investment Research
Abbott and Epic Collaborate to Streamline Glucose Data Access for Providers - The Healthcare Technology Report.
Abbott Laboratories' segment revenues from 2017 to 2024 - Statista
3 Magnificent Stocks That Are Passive Income Machines - The Globe and Mail
Abbott (ABT) Up 1.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
North America Weight Management Products Market Report 2025-2033 Featuring Abbott, Nestle, Herbalife, Woodbolt, Premier Nutrition, Iovate, Kellogg, Ultimate Nutrition, Simply Good Foods, GlanbiaResearchAndMarkets.com - FinancialContent
United States Nutraceuticals Market Forecast Report 2025-2033 Featuring PepsiCo, General Mills, Nestle, Kellogg, Herbalife, Danone, Now Foods, Alticor, Red Bull, and Abbott Laboratories - GlobeNewswire
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):